Nancy Ghattas, Vice President, US Oncology Commercial Franchise Head of Immuno Oncology at AstraZeneca, shared a post on LinkedIn:
“Our AstraZeneca team started 2026 off strong last week at the American Society of Clinical Oncology (ASCO) GI Cancers Symposium in San Francisco. We presented more than 20 abstracts across GI cancers, including BTC, colorectal, gastric/GEJ, HCC and pancreatic, and seized the opportunity to deepen our relationships across the medical and advocacy communities so that we can best serve patients facing GI cancers.
Those connections allow us to think bigger, reach further, and maximize our impact in transforming care. We spent valuable time meeting with KEEs to hear what’s happening in the industry as well as connecting with Women in GI Oncology – We Go Together to support talented researchers and scientists.
Some of the most powerful learnings happened at our Gastric and GEJ Cancer Advisory Council, where we heard first-hand from patients about their experiences and the need for specialized support before, during and after treatment. It was a reminder that the work doesn’t stop when we discover new therapy options but continues to ensure we’re truly meeting the needs of every patient at every step.
After wrapping up our first congress of the year, my team and I are energized about the milestones up ahead. We’re pushing the boundaries of science in GI cancers and I can’t wait to share more of our progress in 2026.”
More posts about ASCOGI26.
